右旋兰索拉唑的药理学特点及在胃食管反流病治疗中的应用

Pharmacology of dexlansoprazole and its application in treating gastroesophageal reflux disease

虽然质子泵抑制剂(PPI)在胃食管反流病(GERD)治疗方面取得了很大的成功,但是抑酸时间不足、患者依从性差等挑战仍然存在。近期,美国FDA批准了一种新的PPI药物右旋兰索拉唑(dexlanso-prazole,日本武田公司开发,商品名:DexliantTM),目前主要用于糜烂性食管炎急性期及维持期的治疗,以及非糜烂性胃食管反流疾病烧心症状的控制。该药物采用独特的双层缓释技术,可以维持更长的作用时间,达到更好的抑酸效果,且安全性和耐受性良好。

Although proton pump inhibitors （PPI） have achieved a remarkable success in the management of gastroesophageal reflux disease （GERD）. However, the challenges such as insufficient action duration and poor compliance still exist as the reason for treatment failure. Recently, dexlansoprazole dual delayed release （DDR, Takeda Pharmaceuticals） under the trade name of DexilantTM got approved by FDA, which provides longer duration of action and more effective acid suppression. It is currently approved for the treatment of erosive esophagitis （acute, maintenance） and symptom release of NERD.